Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
axicabtagene ciloleucel + glofitamab
- Development stage
- Unknown
- Lead developer
- Kite Pharma
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Axicabtagene ciloleucel + glofitamab is an investigational combination therapy for large B-cell lymphoma. Axicabtagene ciloleucel is a CD19-directed autologous CAR-T cell therapy that genetically modifies a patient's own T cells to target and kill CD19-expressing B cells. Glofitamab is a bispecific monoclonal antibody that binds both CD20 on B cells and CD3 on T cells, redirecting T cells to kill malignant B cells. This combination aims to enhance anti-tumor immune activity and improve outcomes for patients with relapsed or refractory large B-cell lymphoma, potentially even as a second-line treatment. Multiple phase II clinical trials are underway to assess synergy, safety, and efficacy of this combination, particularly in patients who have not responded to or are ineligible for standard therapies[1][4][5][6].
- Brand names
- YescartaColumvi
- Other names
- axi-cel + glofitamabYescarta + Columvi
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on axicabtagene ciloleucel + glofitamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on axicabtagene ciloleucel + glofitamab.